Get the Stockscreener App
253.25
0.30%
-0.75
Pre-market:
252.00
-1.25
-0.49%
Praxis Precision Medicines Inc stock is traded at $253.25, with a volume of 679.81K.
It is down -0.30% in the last 24 hours and down -23.26% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$254.00
Open:
$258.34
24h Volume:
679.81K
Relative Volume:
1.58
Market Cap:
$7.06B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-18.81
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
-24.44%
1M Performance:
-23.26%
6M Performance:
-6.54%
1Y Performance:
+468.33%
1-Day Range:
$247.59
$266.60
1-Week Range:
$247.59
$321.75
52-Week Range:
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
253.25 | 7.08B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
442.96 | 113.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.34 | 66.62B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.41 | 55.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.16 | 40.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
148.49 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision Medicines Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Transcript : Praxis Precision Medicines, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08 - marketscreener.com
Technical Reactions to PRAX Trends in Macro Strategies - Stock Traders Daily
Praxis down on trial setback for seizure therapy - MSN
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor (PRAX) - Seeking Alpha
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings - Insider Monkey
5 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference - Investing News Network
Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE - RTTNews
PRAX Technical Analysis | Trend, Signals & Chart Patterns | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Praxis Precision Medicines (PRAX) Receives a Buy from LifeSci Capital - The Globe and Mail
TD Cowen Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX) - The Globe and Mail
PRAX Maintained by Oppenheimer -- Price Target Lowered to $650 - GuruFocus
Praxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy Pipeline - Yahoo Finance
PRAX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PRAX Maintains Outperform by Baird -- Price Target Lowered to $4 - GuruFocus
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive - Investor's Business Daily
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Biopharmaceutical Praxis gives new hires stock units vesting over 4 years - Stock Titan
Praxis Precision (PRAX) Sees Major Decline in Stock Value - GuruFocus
H.C. Wainwright cuts Praxis Precision Medicines stock price target on trial miss - Investing.com UK
TD Cowen cuts Praxis Precision Medicines stock price target to $550 on trial miss - Investing.com UK
PRAX Maintained by Deutsche Bank -- Price Target Lowered to $374 - GuruFocus
PRAX Maintained by Wedbush -- Price Target Lowered to $162 - GuruFocus
Truist cuts Praxis Precision Medicines stock price target on trial failure - Investing.com UK
Praxis Precision Medicines slides after vormatrigine POWER1 trial misses primary endpoint - Quiver Quantitative
Oppenheimer Adjusts Praxis Precision Medicines PT to $650 From $750, Maintains Outperform Rating - Moomoo
Praxis Precision Medicines (PRAX) Phase 2/3 Study Fails to Meet Primary Endpoint - GuruFocus
PRAX Maintained by BTIG -- Price Target Lowered to $810 - GuruFocus
Truist cuts Praxis Precision Medicines stock price target on trial failure By Investing.com - Investing.com Australia
TD Cowen cuts Praxis Precision Medicines stock price target to $550 on trial miss By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $162 to $1,201 - Moomoo
H.C. Wainwright cuts Praxis Precision Medicines stock price target on trial miss By Investing.com - Investing.com South Africa
Deutsche Bank Adjusts Praxis Precision Medicines PT to $374 From $420, Maintains Buy Rating - marketscreener.com
Praxis down on trial setback for seizure drug (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines, Inc. Files Form 8-K with SEC Detailing Corporate Information and NASDAQ Listing - Minichart
Why Is Praxis Stock Plunging TodayPraxis Precision Medicine (NASDAQ:PRAX) - Benzinga
Praxis Precision Medicines stock price target lowered to $810 by BTIG - Investing.com South Africa
Praxis pauses one of its seizure programs after phase 2 fail - Fierce Biotech
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint - Sahm
Praxis Precision (PRAX) Sees 15% Drop After POWER1 Study Update - GuruFocus
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - TradingView
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study - marketscreener.com
Praxis Precision Reassesses Vormatrigine After Mixed POWER1 Data - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Praxis Precision Medicines reports Phase 2/3 study results for vormatrigine in epilepsy - Investing.com Nigeria
Praxis Precision Medicines, Inc. announces that its clinical trial has met a key secondary endpoint with a 50% response rate. - Bitget
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):